Cresset Asset Management’s Akari Therapeutics AKTX Stock Holding History

Cresset Asset Management’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211K	Hold	20,561	–	–	﹤0.01%	1567
2026 Q1	$106K	Sell	20,561 -1	-0%	-$9	﹤0.01%	1538
2025 Q4	$238K	Hold	20,562	–	–	﹤0.01%	1415
2025 Q3	$831K	Buy	20,562 +20,102	+4,370%	+$782K	﹤0.01%	808
2025 Q2	$21.5K	Hold	460	–	–	﹤0.01%	1413
2025 Q1	$22.8K	Hold	460	–	–	﹤0.01%	1687
2024 Q4	$22.5K	Hold	460	–	–	﹤0.01%	1709
2024 Q3	$54.3K	Hold	460	–	–	﹤0.01%	2088
2024 Q2	$49.7K	Buy	+460	New	+$33.9K	﹤0.01%	2007
2023 Q3	–	Sell	-271	Closed	-$36.8K	–	1802
2023 Q2	$36.8K	Buy	+271	New	+$39.2K	﹤0.01%	1858

Other funds holding AKTX

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Truvestments Capital Sarasota, Florida $673M AUM 55.24% 1-Year Est. Return

Cresset Asset Management's AKTX Position: Q2 2026 in Review

Cresset Asset Management held its Akari Therapeutics (AKTX) position steady in Q2 2026 at 20,561 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #1567.

Cresset Asset Management first reported a position in AKTX in Q2 2023 and has held it in 10 quarters since. The position peaked at $831K in Q3 2025. 9 funds tracked by Wall St. Rank hold AKTX as of Q2 2026.

Cresset Asset Management held 20,561 shares of Akari Therapeutics worth $211K as of Q2 2026.
Cresset Asset Management left its Akari Therapeutics share count unchanged in Q2 2026.
Akari Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1567 holding.
Cresset Asset Management first reported a position in Akari Therapeutics in Q2 2023 and has held it in 10 quarters since.
Cresset Asset Management's Akari Therapeutics position peaked at $831K in Q3 2025.
9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.